STEMLINE THERAPEUTICS INC's ticker is STML and the CUSIP is 85858C107. A total of 95 filers reported holding STEMLINE THERAPEUTICS INC in Q1 2020. The put-call ratio across all filers is 2.72 and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q1 2020 | $10,658,000 | -53.6% | 2,202,069 | +1.9% | 0.00% | -50.0% |
Q4 2019 | $22,969,000 | +9.8% | 2,160,745 | +7.5% | 0.00% | 0.0% |
Q3 2019 | $20,920,000 | -19.8% | 2,009,596 | +18.0% | 0.00% | 0.0% |
Q2 2019 | $26,099,000 | +23.7% | 1,703,585 | +3.8% | 0.00% | 0.0% |
Q1 2019 | $21,098,000 | +115.0% | 1,641,900 | +59.0% | 0.00% | +100.0% |
Q4 2018 | $9,811,000 | -34.3% | 1,032,719 | +14.8% | 0.00% | 0.0% |
Q3 2018 | $14,934,000 | -10.9% | 899,583 | -13.9% | 0.00% | 0.0% |
Q2 2018 | $16,768,000 | +22.4% | 1,044,477 | +16.6% | 0.00% | 0.0% |
Q1 2018 | $13,700,000 | +138.2% | 895,432 | +142.9% | 0.00% | – |
Q4 2017 | $5,751,000 | +48.2% | 368,672 | +5.5% | 0.00% | – |
Q3 2017 | $3,880,000 | +22.1% | 349,585 | +1.2% | 0.00% | – |
Q2 2017 | $3,179,000 | +19.8% | 345,363 | +11.3% | 0.00% | – |
Q1 2017 | $2,653,000 | -1.5% | 310,247 | +23.2% | 0.00% | – |
Q4 2016 | $2,694,000 | +8.1% | 251,804 | +9.2% | 0.00% | – |
Q3 2016 | $2,493,000 | +67.0% | 230,508 | +4.4% | 0.00% | – |
Q2 2016 | $1,493,000 | +48.1% | 220,768 | +1.9% | 0.00% | – |
Q1 2016 | $1,008,000 | -23.9% | 216,571 | +3.3% | 0.00% | – |
Q4 2015 | $1,325,000 | -21.7% | 209,687 | +9.3% | 0.00% | – |
Q3 2015 | $1,693,000 | -24.0% | 191,774 | +1.3% | 0.00% | – |
Q2 2015 | $2,228,000 | -15.0% | 189,380 | +4.5% | 0.00% | – |
Q1 2015 | $2,622,000 | -15.1% | 181,230 | -0.0% | 0.00% | – |
Q4 2014 | $3,089,000 | +37.0% | 181,259 | +0.1% | 0.00% | – |
Q3 2014 | $2,254,000 | +4.8% | 181,079 | +23.5% | 0.00% | – |
Q2 2014 | $2,150,000 | -24.6% | 146,603 | +4.6% | 0.00% | – |
Q1 2014 | $2,851,000 | -1.6% | 140,124 | -5.0% | 0.00% | – |
Q4 2013 | $2,896,000 | -58.7% | 147,541 | -4.7% | 0.00% | -100.0% |
Q3 2013 | $7,011,000 | +183.7% | 154,759 | +49.2% | 0.00% | – |
Q2 2013 | $2,471,000 | – | 103,752 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Lyon Street Capital, LLC | 1,471,518 | $23,618,000 | 8.40% |
INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 492,930 | $7,862,000 | 3.02% |
Consonance Capital Management LP | 2,747,198 | $44,093,000 | 2.84% |
NEXTHERA CAPITAL LP | 559,517 | $8,980,000 | 1.39% |
Eventide Asset Management | 1,086,400 | $17,437,000 | 0.72% |
Virtus ETF Advisers LLC | 45,850 | $736,000 | 0.65% |
KNOTT DAVID M | 90,000 | $1,445,000 | 0.54% |
Polar Capital LLP | 1,912,605 | $30,697,000 | 0.18% |
Artal Group S.A. | 400,000 | $6,420,000 | 0.14% |
J. Goldman & Co LP | 100,000 | $1,605,000 | 0.08% |